An observational study in Functional Constipation (FC), Fecal Microbiota Transplantation and Type 2 Diabetes Mellitus (T2DM), sponsored by Shanghai 10th People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Shanghai 10th People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.
Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 138th largest by enrollment of the 143 observational ones that give a count, is one of 51 that started in 2020, is one of 143 observational ones, and was the 913th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
BrightGene Bio-Medical Technology Co., Ltd. · Sites in China
Ages 18–75
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
913 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 143 · Phase 2 90 · Phase 3 216 · Phase 4 155
First in 1998; this study’s year is marked. 51 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 300 across 1,748 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 192 across the 769 interventional studies, 556 across the 143 observational. Of the 521 that completed or were terminated, 123 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
448 of 913 have an industry lead sponsor. The 10 most frequent:
Shanghai 10th People's Hospital is the lead sponsor of 168 studies on the registry; 45 are open to participants now.
Shanghai 10th People's Hospital has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
56 of the studies in Diabetes Mellitus, Type 2 with a site in China that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
| NCT07082114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | 2027-02-16 |
| NCT07156500Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | 2027-03-30 |
| NCT07156539Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM | 2027-03-30 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 56 to your calendar (.ics) → With an account.
Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to retrospectively evaluate the clinical effectiveness and safety of fecal microbiota transplantation (FMT) in treating patients with functional constipation (FC) who also have type 2 diabetes mellitus (T2DM). It analyzes changes in bowel function, glucose metabolism indicators, and gut microbiota structure before and after FMT, and further explores the relationship between donor-related microbiota remodeling, predicted microbial metabolic functions, and clinical outcomes.
Adults aged ≥18 years with Rome IV-diagnosed functional constipation complicated by T2DM who received FMT at a single center (2020-2024) and had complete data at baseline (FMT-0) and day 30 (FMT-30); exclusions were pregnancy, malignancy, severe comorbidity, immunosuppression, antibiotics/probiotics or prior FMT within 4 weeks, and incomplete records or loss to follow-up. A total of 30 patients were analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FMT-0 is the baseline assessment immediately before the first FMT infusion. Data were retrieved retrospectively from electronic medical records. Each patient served as his or her own control.
The same patients, assessed 30 days after completing the FMT course (primary efficacy time point), to compare pre- and post-treatment clinical indices and gut microbiota. FMT: oral vancomycin 500 mg twice daily for 3 days, then 2 L polyethylene glycol bowel cleansing, then frozen fecal suspension infused via nasojejunal tube once daily for 6 days.
Change in spontaneous bowel movement (SBM) frequency
Compare the number of times patients have spontaneous bowel movements per week before FMT treatment and 30 days after treatment to assess improvement in constipation symptoms. Calculation formula: ΔSBM = SBM30 - SBM0. An increase in the number means more spontaneous bowel movements per week.
Time frame: 30 days
Fasting blood sugar (FPG) changes
Compare patients' fasting blood glucose levels before FMT treatment and 30 days after treatment to evaluate changes in glucose metabolism indicators. Calculation formula: ΔFPG = FPG0 - FPG30. An increase in the value indicates a decrease in fasting blood glucose.
Time frame: 30 days
Ran from Jan 2020 to primary completion in Dec 2024, 59 months.
Of 435 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's 59 months is above that.
Counting every sponsor, half of 605 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai 10th People's Hospital →